^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:luminespib (AUY922) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    AUY922 in Patient With Stage IV NSCLC

    Excerpt:
    ...- EGFR mutations in exon 20 T790M....
    Trial ID:
    NCT01922583
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

    Excerpt:
    In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC….Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild type of all three....Biomarker data showed activity of AUY922 in EGFR-mutant patients with exon 19 deletion, T790M mutation, and exon 20 insertion....AUY922 is active in patients with NSCLC, particularly among patients with ALK rearrangements and EGFR mutations.
    DOI:
    https://doi.org/10.1016/j.jtho.2017.11.131
    Trial ID:
    NCT01124864